



INITIAL

Complete sections 1, 2 & 3

RENEWAL

Complete sections 1, 2 & 4

For up to date criteria and forms, please check: www.gov.bc.ca/pharmacarespecialauthority

Fax requests to 1 800 609-4884 (toll free) OR mail requests to: PharmaCare, Box 9652 Stn Prov Govt, Victoria, BC V8W 9P4

This facsimile is Doctor-Patient privileged and contains confidential information intended only for PharmaCare. Any other distribution, copying or disclosure is strictly prohibited. If you have received this fax in error, please write "MIS-DIRECTED" across the front of the form and fax toll-free to 1 800 609-4884, then destroy the pages received in error.

If PharmaCare approves this Special Authority request, approval is granted solely for the purpose of covering prescription costs. PharmaCare approval does not indicate that the requested medication is, or is not, suitable for any specific patient or condition.

Forms with information missing will be returned for completion. If no prescriber fax or mailing address is provided, PharmaCare will be unable to return a response.

SECTION 1 - PRESCRIBING NEUROLOGIST'S INFORMATION

Form for Section 1 containing fields for Prescriber's Name and Mailing Address, Mail Confirmation, College ID, MSP Number, Phone Number, and Prescriber's Fax Number.

SECTION 2 - PATIENT INFORMATION

Form for Section 2 containing fields for Patient (Family) Name, Patient (Given) Name(s), Date of Birth, Date of Application, and Personal Health Number (PHN).

SECTION 3 - INITIAL COVERAGE FOR FINGOLIMOD (GILENYA), 0.5 mg once daily: ONE YEAR FINGOLIMOD: 9901-0228

- Checkboxes for clinical criteria: As second-line monotherapy, Prescribed by a neurologist, EDSS score 5.5 or less, and Patient has not experienced a heart attack or stroke.

PLUS, for patients meeting ALL of the following:

- Additional checkboxes for MRI findings, relapses, and treatment response criteria.

Table with 4 columns: Name of Previous Disease Modifying Agent, Dose, Duration of Trial (Months), and Details of Outcome (Failure, Contraindication, Intolerance, Other). Rows 1 and 2 for patient history.

Please complete additional information on page 2 >>

PHARMACARE USE ONLY

Table with 3 columns: STATUS, EFFECTIVE DATE (YYYY / MM / DD), and DURATION OF APPROVAL.

Patient (Family) Name	Patient (Given) Name(s)	Personal Health Number (PHN)
-----------------------	-------------------------	------------------------------

SECTION 4 – RENEWAL COVERAGE FOR FINGOLIMOD (GILENYA), 0.5 mg once daily monotherapy: TWO YEARS

- As second-line monotherapy for the treatment of relapsing-remitting multiple sclerosis.
- Prescribed by a neurologist from a designated multiple sclerosis clinic.
- Improvement or stability of EDSS score. Most recent EDSS score: _____ date: _____

PLUS, evidence of continued benefit (improvement or stabilization) as shown by at least ONE of the following:

- A. Reduction in relapse rate (decrease from _____ relapses per year to _____ relapses per year).
- B. MRI scan: Reduction or stability in lesion load.
- C. MRI scan: Reduction in gadolinium enhancing lesions.
- D. Overall clinical impression of benefit.

**Report all adverse events to the post-market surveillance program, Canadian Vigilance,
toll-free 1-866-234-2345 (health professionals only).**

Personal information on this form is collected, used and disclosed under the authority of, and in accordance with, the *British Columbia Pharmaceutical Services Act* and *Freedom of Information and Protection of Privacy Act*. It will not be disclosed to any persons without the patient's consent. The information you provide will be relevant to and used solely to (a) provide PharmaCare benefits for the medication requested, (b) to implement, monitor and evaluate this and other Ministry programs, and (c) to manage and plan for the health system generally. If you have any questions about the collection or use of this information, call Health Insurance BC from Vancouver at 1-604-683-7151 or from elsewhere in BC toll free at 1-800-663-7100 and ask to consult a pharmacist concerning the Special Authority process.

I have discussed with the patient that the purpose of releasing their information to PharmaCare is to obtain Special Authority for prescription coverage and for the purposes set out here.

Neurologist's Signature (Mandatory)

PharmaCare may request additional documentation to support this Special Authority request.

Actual reimbursement is subject to the rules of a patient's PharmaCare plan, including any annual deductible requirement, and to any other applicable PharmaCare pricing policy.